$BNTC
Benitec Biopharma Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Hayward, CA
BNTC chart
What traders are saying about $BNTC
Latest postsBenitec Biopharma Inc. news
- Raymond James Initiates Benitec Biopharma(BNTC.US) With Buy Rating, Announces Target Price $14
Moomoo ·
- Benitec Biopharma Inc. Estimates – NASDAQ:BNTC
TradingView ·
- BNTC Initiated Coverage by Raymond James -- Rating Outperform
GuruFocus ·
- This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Benzinga ·
- Raymond James initiates Benitec BioPharma stock with outperform rating
Investing.com ·
- Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study
Yahoo Finance ·
- After Plunging 23.9% in 4 Weeks, Here's Why the Trend Might Reverse for Benitec Biopharma (BNTC)
Yahoo Finance ·
- Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
Yahoo Finance ·
- Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
Yahoo Finance ·
- Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Yahoo Finance ·
- Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)
Yahoo Finance ·
- Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Yahoo Finance ·
Benitec Biopharma Inc. key financials
| USD | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Net income | -$45.7M | -$37.9M | -$21.8M | -$19.6M |
| Diluted EPS | $-0.98 | $-1.05 | $-1.22 | $-14.12 |
| Total assets (year end) | – | $190.7M | $79.1M | $21.4M |
| Cash and equivalents (year end) | – | $188.8M | $78.3M | $20.4M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Benitec Biopharma Inc.
- Ticker
- BNTC (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Hayward, CA
- Incorporated in
- DE
- Fiscal year end
- June 30
- SEC CIK
- 1808898
Frequently asked questions
What exchange is Benitec Biopharma Inc. listed on?
Benitec Biopharma Inc. trades on the Nasdaq under the ticker symbol BNTC.
What industry is Benitec Biopharma Inc. in?
Benitec Biopharma Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Benitec Biopharma Inc. headquartered?
Benitec Biopharma Inc.'s business address on file with the SEC is in Hayward, CA.
When does Benitec Biopharma Inc.'s fiscal year end?
Benitec Biopharma Inc.'s fiscal year ends on June 30.
How much revenue did Benitec Biopharma Inc. report?
Benitec Biopharma Inc. reported $59,000 in revenue for calendar year 2021, according to its SEC filings.